Urpu Salmenniemi
Overview
Explore the profile of Urpu Salmenniemi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luft T, Gras L, Koster L, Kroger N, Schroder T, Platzbecker U, et al.
Am J Hematol
. 2024 Nov;
100(1):38-51.
PMID: 39605194
Prophylaxis strategies for Graft versus host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) frequently encompass a combination of a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate mofetil...
2.
Nihtila J, Penna L, Salmenniemi U, Itala-Remes M, Crossland R, Gallardo D, et al.
Sci Rep
. 2024 Nov;
14(1):26988.
PMID: 39506082
Natural killer (NK) cells recognize and may kill malignant cells via their cell surface receptors. Killer cell immunoglobulin-like receptor (KIR) genotypes of donors have been reported to adjust the risk...
3.
Jahan F, Penna L, Luostarinen A, Veltman L, Hongisto H, Lahteenmaki K, et al.
Sci Rep
. 2024 Nov;
14(1):26678.
PMID: 39496674
Natural killer (NK) cells are a promising allogeneic immunotherapy option due to their natural ability to kill tumor cells, and due to their apparent safety. This study describes the development...
4.
Lambert N, Forte F, Moussaoui M, Monseur J, Raus N, Polushin A, et al.
Brain
. 2024 Oct;
PMID: 39442000
Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this...
5.
Larue M, Labopin M, Schroeder T, Huang X, Blau I, Schetelig J, et al.
Hemasphere
. 2024 Oct;
8(10):e70026.
PMID: 39440198
Information on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left-truncated analysis of long-term survival in patients with...
6.
Arrieta-Bolanos E, Bonneville E, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, et al.
J Clin Oncol
. 2024 Aug;
42(28):3287-3299.
PMID: 39167735
PURPOSEHuman leukocyte antigen (HLA) mismatching can reduce survival of patients with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in HCT practice, in particular graft-versus-host disease (GVHD) prophylaxis...
7.
Nagler A, Labopin M, Salmenniemi U, Wu D, Blaise D, Rambaldi A, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1563-1576.
PMID: 39164484
We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and...
8.
Arrieta-Bolanos E, van der Burg L, Gedde-Dahl T, Robin M, Salmenniemi U, Kroger N, et al.
Blood
. 2024 Aug;
144(16):1747-1751.
PMID: 39102621
HLA-DP permissive mismatches can be assigned a direction according to their immunopeptidome divergence across core and noncore subsets. Noncore permissive graft-versus-host mismatches show significantly reduced risks of relapse without increased...
9.
Al Hamed R, Labopin M, Wu D, Gedde-Dahl T, Aljurf M, Forcade E, et al.
Bone Marrow Transplant
. 2024 Aug;
59(10):1458-1465.
PMID: 39095548
Core-binding factor acute myeloid leukemia (CBF-AML) represents 12-15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction...
10.
Giebel S, Labopin M, Peric Z, Passweg J, Blaise D, Salmenniemi U, et al.
Transplant Cell Ther
. 2024 Jul;
31(1):14.e1-14.e10.
PMID: 39069077
The use of tyrosine kinase inhibitors (TKIs) during induction and consolidation, followed by allogeneic hematopoietic cell transplantation (allo-HCT), is a standard of care for patients with Philadelphia (Ph)-positive acute lymphoblastic...